NIJMEGEN, The Netherlands – September 1, 2025
Khondrion, a Phase 3 clinical-stage biopharmaceutical company advancing therapies for primary mitochondrial diseases, today announced the appointment of Jasper Levink as its new Chief Executive Officer. He succeeds Prof. Jan Smeitink, the founder and CEO of Khondrion and a lifelong advocate formitochondrial medicine.
This leadership transition marks a pivotal moment for Khondrion as it prepares to enroll the first patient in its registrational Phase 3 trial for its lead candidate targeting m.3243A>G primary mitochondrial disease, a progressive and debilitating condition with high unmet medical need.
Prof. Smeitink, who will take on the role of Chairman of the Supervisory Board, shared:
“After decades dedicated to the mitochondrial disease community—as a clinician, researcher, and biotech founder—I am proud to pass the leadership baton to Jasper. His strategic vision and experience make him the ideal person to guide Khondrion through this exciting next chapter.
Jasper Levink brings extensive experience in life sciences strategy, entrepreneurship, and biotech leadership. His appointment signals Khondrion’s commitment to accelerating development, strengthening partnerships, and preparing for potential commercialization.
“I am honored to lead Khondrion at such a transformative time,” said Jasper. “With a passionate team and strong scientific foundation, we are on the cusp of potentially delivering the first approved therapy for patients with multi-system mitochondrial disease. I look forward to working closely with Jan and the Board as we bring this important treatmentcloser to patients.”
Details on Prof. Smeitink’s new role and strategic board initiatives will be shared in the coming weeks.
E-mail: levink@khondrion.com
Tel: +31 24 763 50 00
Website: www.khondrion.com
